/stocks — the workspaceLOADING
All RANI SEC filings, by type → · Earnings date & implied move · Search inside filings
Rani Therapeutics Holdings, Inc. (RANI) is a pharmaceutical preparations company. Piotroski F-Score 4/7. 3 insider Form 4 filings in the last 90 days. Next earnings projected around 2026-11-05 from RANI's year-over-year reporting pattern (not yet company-confirmed). Fundamentals from SEC filings; prices are end-of-day.
What’s behind RANI’s latest move — the size, how unusual the volume is, and the catalyst on the tape, explained and cited to the source.
End-of-day bars · delayed, not real-time · data: Databento · studies computed in your browser from these barsCharting by TradingView Lightweight Charts™
FY ending 2025-12-31 vs 2024-12-31.
No sensitivity grid: free cash flow is not positive, so the DCF gives no value at any growth or discount rate.
Estimates, not targets. The DCF treats free cash flow as cash flow to equity and divides by shares (the common retail shortcut — it skips net debt and a full WACC), so it’s a sanity-check, not a valuation opinion. All inputs are from RANI’s SEC filings; change any assumption above and the numbers update live. Educational only — not investment advice.
A plain-English read on RANI plus an auto-SWOT — built from RANI's SEC filings and market data, every point cited, nothing invented. Educational, not investment advice.
Four AI analysts — a bull, a bear, a risk manager, and a PM — debate RANI using only the SEC-filing and market facts below. Every point cites its evidence; nothing is invented. This is educational research, not investment advice.
Educational only — not financial advice. Data from SEC EDGAR public filings; no live market data is shown. Figures reflect the company's own reported XBRL facts and may lag.
XBRL company facts, SEC EDGAR. TTM = last four reported quarters. Valuation ratios arrive with a price source — we don't fake quotes.
Has RANI been issuing shares? Offering history →
↓ Download the fiscal-year statement table: XLSX · CSV · revenue, income, EPS, cash flow, balance sheet · from SEC XBRL, dated
As filed. We do not recategorize line items. Each chart plots one XBRL concept exactly as RANI tagged it: revenue us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, net income us-gaap:NetIncomeLoss, EPS us-gaap:EarningsPerShareDiluted, period by period; a period the company did not tag on its own is left out, not estimated. A figure that disagrees with the filing is a bug in our extraction, not a policy, and we fix it: report a mismatch.
No lawmaker has disclosed a trade in RANI under the STOCK Act.
Projected from RANI's own SEC 8-K filing history — the year-over-year reporting pattern (about 47% land the exact day, about 91% within a week, measured across 4,713 past reports). No analyst estimates and nothing invented, and every confirmed date links to the source it came from, so you can check it yourself. It upgrades the momentRANI files or announces.
RANI has sold off after 8 of its last 8 earnings reports.
Each figure is one earnings reaction — how much RANI moved from the closing price the day before a report to the close the day after. Based on its last 8 reports.
Large earnings reactions have been common.
RANI has traded lower after most recent earnings releases.
The average is inflated by its most volatile prints (+-0.8% and -28.9%).
A more typical earnings reaction has been approximately ±9.4%.
Realized close-to-close history only — no options-implied move, no analyst estimates.
| Reported | Close-to-close |
|---|---|
| 2026-08-13 | -0.8% |
| 2026-05-15 | -12.4% |
| 2026-03-26 | -28.9% |
| 2025-11-06 | -19.2% |
| 2025-08-07 | -3.9% |
| 2025-05-13 | -9.2% |
| 2025-03-31 |
Earnings dates are the company's 8-K Item 2.02 filings (SEC). Reactions from Databento EOD.
| -9.6% |
| 2024-11-14 | -8.1% |
None of the 5 estimators could run on RANI's filings.
One estimator is a point estimate, not a range, so no band and no valuation label are published for RANI. Below is everything that was checked, so the refusal can be read rather than taken on trust.
Nothing produced a value.
No fiscal year of price history was on record; the historical multiples need 5. No sector peer set is priced for RANI, so sector medians could not fill the gaps.
Every refusal recorded for RANI → · How often we decline, and why →
No tracked institution reported a position in RANI in the latest 13F round.
Every registered fund files its complete portfolio with the SEC. These weights come from those filings, so each one carries the period it describes. Holdings are quarterly and filed in arrears — the figures below are as of 2026-06-30, not today.
| Fund | Weight | As of |
|---|---|---|
| VTI Vanguard Total Stock Market ETF | <0.01% | 2026-06-30 |
Drawn from 39 large US equity funds we scan, not every fund in existence, so a missing fund means we do not scan it rather than that it holds none. Holdings are joined to tickers by issuer name, which does not resolve every position; what that misses is published.
Head office: San Jose, California, United States · the company’s charter and its head office are in different states.
EDGAR’s company directory says California, United States. We show the company’s own most recent filing. The directory is a separate record, and the two can differ in either direction: a directory entry can change before the next filing shows a reincorporation, or go on showing a jurisdiction the company has left.
Source: the cover page of Rani Therapeutics Holdings, Inc.’s 10-Q filed 2026-08-13, on EDGAR. Filings checked 2026-10-25. Incorporation is where the company’s charter was filed. It is not where the business operates or earns, which no filing cover states. How this works
Of 2 sales in the last ~6 months, 0 were filed with the Rule 10b5-1 box checked, set up in advance under a written trading plan; 2 were filed without it.
| IMRAN MIR ADirector | BUY | $25K | view → |
| Javadi AlirezaChief Technical Officer | SELL | $0K | view → |
| Imran TalatChief Executive Officer | BUY | $25K | view → |
| Imran TalatChief Executive Officer | SELL | $11K | view → |
2 of the 2 checks that ran found nothing new for RANI. 2 could not run.
Each event check looks back 30 days from the date its own source was stored, read or generated, never from the date this page was built. A check that finds nothing is a measurement of that window, not a forecast, and a check that cannot be dated does not make the claim at all.
From SEC Form 4 and 13F filings. Both are backward-looking disclosures on different reporting clocks, and neither predicts price. Educational information only — not investment advice.